Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Neurocrine Biosciences is a biotechnology company focused on discovering, developing, and marketing treatments for neurological and endocrine-related diseases. The San Diego-based company is best ...

Q4 2024 Earnings Call Transcript January 31, 2025 Revvity, Inc. misses on earnings expectations. Reported EPS is $0.778 EPS, expectations were $1.37. Operator: Hello, everyone, and welcome to ...

Hello, everyone, and welcome to Revvity's fourth-quarter 2024 earnings call. My name is Lydia, and I will be your operator today. (Operator Instructions) I'll now hand you over to Steve Willoughby, ...

SAN DIEGO, January 13 ... workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

SAN DIEGO (FOX 5/KUSI) — San Diego is expected to get hit by its first major storm of the year this week following the single slowest start to the region’s typical “rainy season” in ...

A winter storm that arrived Wednesday night in San Diego made for cold, wet and windy conditions at the Torrey Pines Golf Course. It prompted Scottie Scheffler, the world’s top-ranked player, ...